Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immunovia AB logo — Advancing early detection of pancreatic cancer

Immunovia AB

Advancing early detection of pancreatic cancer

Founded 2007 Sweden Sweden 17 employees Grant Biotechnology, Health Care

General Information

Company Name Immunovia AB
Founded Year 2007
Location Sweden Sweden
Employees 17
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Immunovia AB. To contact Immunovia AB, visit immunovia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Immunovia AB

Immunovia AB is a diagnostic company focused on revolutionizing early cancer detection. The company is leveraging its proprietary test platform, called IMMray™, to develop highly accurate blood tests for the early detection of cancer and autoimmune diseases. Utilizing advanced machine-learning and bioinformatics, the tests identify a set of relevant biomarkers indicative of specific diseases, forming a unique "disease biomarker signature." Founded in 2007 as a result of pioneering cancer studies and research at Lund University and CREATE Health Cancer Center in Sweden, Immunovia's first product, IMMray™ PanCan-d, is undergoing clinical evaluation in major studies for high-risk groups in pancreatic cancer, including PanFAM-1, PanSYM-1, and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA to further its presence in the market. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, visit their websites, www.immunovia.com and www.immunoviainc.com. The company has not disclosed its latest investment details or investors.

No funding data available for Immunovia AB yet.

Immunovia AB Alternatives & Competitors

Immunovia AB vs
NAVERIS
NAVERIS United States

Transformative Technologies for Early Cancer Detection.

Venture round
88 employees
Biotechnology, Health Care
Immunovia AB vs
Beacon Biomedical
Beacon Biomedical United States

Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-19 detecti...

Acquired
1 employees
Biotechnology, Health Care
Immunovia AB vs
Elypta
Elypta Sweden

Advancing cancer detection

Grant
32 employees
Biotechnology, Health Care

FAQ About Immunovia AB

Advancing early detection of pancreatic cancer
Immunovia AB was founded in 2007.
Immunovia AB is headquartered in Sweden.
Immunovia AB operates in Biotechnology and Health Care.
Immunovia AB has approximately 17 employees.
Top alternatives and competitors to Immunovia AB include NAVERIS, Beacon Biomedical, Elypta, ABCODIA LIMITED, Savicell. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunovia AB and NAVERIS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Immunovia AB, https://bouncewatch.com/company/immunovia-ab, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes